Understanding COVID-19: in the end it is the endothelium-what else?
作者信息
Lüscher Thomas F
机构信息
Professor of Cardiology, Imperial College, and Director of Research, Education & Development, Royal Brompton and Harefield Hospitals London, UK.
Professor and Chairman, Center for Molecular Cardiology, University of Zurich, Switzerland.
出版信息
Eur Heart J. 2020 Aug 21;41(32):3023-3027. doi: 10.1093/eurheartj/ehaa706.
Abstract
摘要
相似文献
1
Understanding COVID-19: in the end it is the endothelium-what else?了解新型冠状病毒肺炎：归根结底是内皮细胞的问题——还能有什么别的呢？
Eur Heart J. 2020 Aug 21;41(32):3023-3027. doi: 10.1093/eurheartj/ehaa706.
2
At the heart of COVID-19.新冠疫情的核心
Eur Heart J. 2020 May 14;41(19):1830-1832. doi: 10.1093/eurheartj/ehaa415.
3
Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19.血管紧张素转换酶2（ACE2）水平降低可能介导了新型冠状病毒肺炎（COVID-19）的血栓前状态。
Eur Heart J. 2020 Sep 1;41(33):3198-3199. doi: 10.1093/eurheartj/ehaa534.
4
The Impact of COVID-19 on Italy: A Lesson for the Future.新冠疫情对意大利的影响：未来之鉴。
Int J Occup Environ Med. 2020 Jul 10;11(3):151-152. doi: 10.34172/ijoem.2020.1984. Epub 2020 Mar 30.
5
COVID-19 and Congenital Heart Disease: Perspectives From a Resource-limited Setting.新型冠状病毒肺炎与先天性心脏病：资源有限环境下的观点
Indian Pediatr. 2020 Aug 15;57(8):771-772. doi: 10.1007/s13312-020-1939-y. Epub 2020 May 28.
6
Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy.意大利北部新冠疫情期间自身免疫性肝病患者的健康状况
J Hepatol. 2020 Sep;73(3):702-705. doi: 10.1016/j.jhep.2020.05.008. Epub 2020 May 12.
7
The cardiovascular burden of congenital heart disease - not only in times of COVID-19.先天性心脏病的心血管负担——不仅在新冠疫情期间如此。
Int J Cardiol. 2020 Oct 1;316:106. doi: 10.1016/j.ijcard.2020.05.071. Epub 2020 Jul 13.
8
Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy.新型冠状病毒肺炎住院患者中严重急性呼吸综合征冠状病毒2诱导的凝血病与预后：来自意大利的一则简讯
Thromb Haemost. 2020 Aug;120(8):1233-1236. doi: 10.1055/s-0040-1712918. Epub 2020 May 26.
9
COVID-19 in Italy: passing through bitter waters.意大利的 COVID-19：苦水已过。
Eur Respir J. 2020 Jul 30;56(1). doi: 10.1183/13993003.01812-2020. Print 2020 Jul.
10
Response to the letter, "The cardiovascular burden of congenital heart disease - not only in times of COVID-19".对题为《先天性心脏病的心血管负担——不仅在新冠疫情期间》这封信的回复。
Int J Cardiol. 2020 Nov 1;318:52. doi: 10.1016/j.ijcard.2020.05.081. Epub 2020 May 29.
引用本文的文献
1
Effects of COVID-19 and medication used for treatment and symptom prevention on the antioxidant status.2019冠状病毒病及其治疗和症状预防用药对抗氧化状态的影响。
Pharmacol Rep. 2025 Apr;77(2):490-499. doi: 10.1007/s43440-025-00696-8. Epub 2025 Feb 3.
2
Prevention and Treatment of Life-Threatening COVID-19 May Be Possible with Oxygen Treatment.通过氧疗可能预防和治疗危及生命的新型冠状病毒肺炎。
Life (Basel). 2022 May 19;12(5):754. doi: 10.3390/life12050754.
3
"LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.“长新冠”-理解生物学基础和药物治疗策略的假说。
Pharmacol Res Perspect. 2022 Feb;10(1):e00911. doi: 10.1002/prp2.911.
4
Relationship between out-of-hospital cardiac arrests and COVID-19 during the first and second pandemic wave. The importance of monitoring COVID-19 incidence.院外心脏骤停与第一波和第二波大流行期间的 COVID-19 之间的关系。监测 COVID-19 发病率的重要性。
PLoS One. 2021 Nov 19;16(11):e0260275. doi: 10.1371/journal.pone.0260275. eCollection 2021.
5
Thrombosis, an important piece in the COVID-19 puzzle: From pathophysiology to therapy.血栓形成，新冠疫情谜团中的重要一环：从病理生理学到治疗
Anatol J Cardiol. 2021 Sep;25(9):601-608. doi: 10.5152/AnatolJCardiol.2021.475.
本文引用的文献
1
How does COVID-19 kill at home and what should we do about it?新冠病毒在家庭环境中是如何致人死亡的，我们又该如何应对？
Eur Heart J. 2020 Jul 1;41(32):3055-3057. doi: 10.1093/eurheartj/ehaa599.
2
COVID-19 is, in the end, an endothelial disease.COVID-19 归根结底是一种血管内皮疾病。
Eur Heart J. 2020 Sep 1;41(32):3038-3044. doi: 10.1093/eurheartj/ehaa623.
3
Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.肾病患者循环血浆中血管紧张素转换酶2的浓度
Eur Heart J. 2020 Jul 1;41(32):3097-3098. doi: 10.1093/eurheartj/ehaa523.
4
Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes.肾病和糖尿病患者循环血浆血管紧张素转换酶2浓度升高。
Eur Heart J. 2020 Jun 1;41(32):3099. doi: 10.1093/eurheartj/ehaa527.
5
Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19.血管紧张素转换酶2（ACE2）水平降低可能介导了新型冠状病毒肺炎（COVID-19）的血栓前状态。
Eur Heart J. 2020 Sep 1;41(33):3198-3199. doi: 10.1093/eurheartj/ehaa534.
6
Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?心房颤动是否应被视为COVID-19患者预后较差的心血管危险因素？
Eur Heart J. 2020 Jul 1;41(32):3092-3093. doi: 10.1093/eurheartj/ehaa509.
7
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England.COVID-19 大流行与英格兰急性冠状动脉综合征的入院率及治疗管理。
Lancet. 2020 Aug 8;396(10248):381-389. doi: 10.1016/S0140-6736(20)31356-8. Epub 2020 Jul 14.
8
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.新型冠状病毒肺炎患者的肺栓塞：一项法国多中心队列研究。
Eur Heart J. 2020 Jul 1;41(32):3058-3068. doi: 10.1093/eurheartj/ehaa500.
9
COVID-19 and pulmonary embolism: an unwanted alliance.新型冠状病毒肺炎与肺栓塞：一种不良组合。
Eur Heart J. 2020 Jul 1;41(32):3069-3071. doi: 10.1093/eurheartj/ehaa553.
10
Effects of COVID-19 lockdown strategies on management of atrial fibrillation.2019冠状病毒病封锁策略对心房颤动管理的影响。
Eur Heart J. 2020 Sep 1;41(32):3080-3082. doi: 10.1093/eurheartj/ehaa538.
Zotero 插件